SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma, today announced financial results for the third quarter of 2026, along with recent product highlights and corporate updates. “We are approaching a defining period for Zai Lab, as we advance toward bringing our first internally developed innovative medicines to patients globally,” said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. “The

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.